In our study, all women with breast cancer received anthracycline-based chemotherapy (FEC, AC, or EC), with or without Paclitaxel/Docetaxel, and in some cases combined with anti-HER2 therapy (trastuzumab ± pertuzumab). Here, ERBB2 is linked to breast carcinoma.